Get Started

Artificial Intelligence | Machine Learning Eyevensys | Leveraging The Power Of Electroporation

Consumer, Biotechnology, Gene Therapy, Medical Technology, Medical Solutions, Medical Science, Therapeutic Eva Paris , France

Artificial Intelligence | Machine Learning

Eyevensys | Leveraging The Power Of Electroporation

Biotechnology, Gene Therapy, Medical Technology, Medical Solutions, Medical Science, Therapeutic Eva

Paris , France

Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. EyeCET stands for the eye ciliary muscle electro-transfection technology, which uses electroporation to deliver plasmids coding for therapeutic proteins in the eye. EyeCET is safe and non-viral, and it enables the ciliary muscle cells to sustainably produce therapeutic proteins locally.

Total Funding: N/A

Funding Stage: N/A

Business Stage: Scaling Up

Market: B2C

Company Size: 1 to 25

Founded: 2018

Sep 2021

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Mar 2020

Eyevensys Announces Executive Leadership Team Expansion

Date

Round

$ Raised

Investors

08/04/2021

Series B

$12M

Korea Investment Partners

Date : 08/04/2021

Round: Series B

$ Raised: $12M

Investors: Korea Investment Partners

For AI/ML Startup Founders

Get introduced to VC/PE/CVC investors

Signup and Get Started

For Investors at VC/PE firms

Get introduced to AI/ML Startup founders or founders at Eyevensys

Patricia Zilliox
Chief Executive Officer

Ronald Buggage
Chief Medical Officer

Karine Bigot
Head of Pharmacology and Toxicology

Eyevensys - Manage Profile

Eyevensys is growing. Want to work at Eyevensys? Eyevensys is hiring. Join team at Eyevensys

World's Most Promising AI/ML Startups